Uncategorized
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
Apnimed eyes up to $160M IPO to prep for sleep apnea drug launch
If the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total. Read More